Scientists developed a new enzyme-based, template-independent RNA oligonucleotide synthesis technology (eRNA), offering a sustainable alternative to traditional chemical methods for manufacturing RNA therapeutics. RNA oligonucleotides have become increasingly important in treating diseases, with chemical synthesis methods facing challenges in scalability, atom economy, and process mass intensity. Scientists from Wyss Institute at Harvard University developed an aqueous-based enzymatic platform using mutant variants of CID1 poly(U) polymerase and reversible terminator nucleotides with a 3′-O-allyl ether blocking group. This platform enables writing natural and modified RNA oligonucleotides one base at a time without the need for a template sequence. This research achieved an average coupling efficiency of 95% and successfully demonstrated the synthesis of natural and modified RNA sequences up to ten cycles. The enzymatic process was also adapted to a solid-phase format, showing promise for large-scale production. Additionally, the researchers developed a method for removing the initiator sequence using endonuclease V, enhancing the purity of the final product. The enzymatic synthesis platform offers a more sustainable, efficient, and scalable method compared to traditional chemical synthesis, with the potential to meet the growing demand for RNA-based medicines while reducing environmental impact. Congratulations to all the contributors！ Daniel Wiegand Jonathan Rittichier Erkin Kuru George Church EnPlusOne Biosciences Reference: https://lnkd.in/eHRpKG5b #RNA #RNAtherapy #RNAtherapeutics #oligonucleotides #enzymaticsynthesis
Hongene Biotech Corporation’s Post
More Relevant Posts
-
This team selected 3'-O-allyl-rNTPs as choice of reversible terminators for their enzymatic RNA synthesis chemistry. It remains interesting to see if other well known 3'-O-blocking groups, such as 3'-O-azidomethyl and 3'-O-NH2 group, will be reported in the application of enzymatic RNA synthesis.
Scientists developed a new enzyme-based, template-independent RNA oligonucleotide synthesis technology (eRNA), offering a sustainable alternative to traditional chemical methods for manufacturing RNA therapeutics. RNA oligonucleotides have become increasingly important in treating diseases, with chemical synthesis methods facing challenges in scalability, atom economy, and process mass intensity. Scientists from Wyss Institute at Harvard University developed an aqueous-based enzymatic platform using mutant variants of CID1 poly(U) polymerase and reversible terminator nucleotides with a 3′-O-allyl ether blocking group. This platform enables writing natural and modified RNA oligonucleotides one base at a time without the need for a template sequence. This research achieved an average coupling efficiency of 95% and successfully demonstrated the synthesis of natural and modified RNA sequences up to ten cycles. The enzymatic process was also adapted to a solid-phase format, showing promise for large-scale production. Additionally, the researchers developed a method for removing the initiator sequence using endonuclease V, enhancing the purity of the final product. The enzymatic synthesis platform offers a more sustainable, efficient, and scalable method compared to traditional chemical synthesis, with the potential to meet the growing demand for RNA-based medicines while reducing environmental impact. Congratulations to all the contributors！ Daniel Wiegand Jonathan Rittichier Erkin Kuru George Church EnPlusOne Biosciences Reference: https://lnkd.in/eHRpKG5b #RNA #RNAtherapy #RNAtherapeutics #oligonucleotides #enzymaticsynthesis
Template-independent enzymatic synthesis of RNA oligonucleotides - Nature Biotechnology
nature.com
-
Since the COVID mRNA vaccine (even way before it), researchers have realized that mRNA technology has excellent therapeutic potential. However, one limitation of mRNA modality is its short half-life post-transfection. Many efforts have been applied to enhance the half-life (circularization, chemical modification, etc.). Here, Hongyu Chen et al. from MIT showed an innovative approach - by introducing multiple end-modified polyA tails, the authors significantly improved the expression level and stability of their engineered mRNA - detectable 14 days post transfection in vivo! Such a cool paper just came out from Nature Biotechnology!
Branched chemically modified poly(A) tails enhance the translation capacity of mRNA - Nature Biotechnology
nature.com
-
RNA Transcriptomics Market Size, Share & Trends Analysis Report By Technology (Real Time-PCR (qPCR) Technology, Microarray Technology, Sequencing Technology, Others), By Application (Construction of RNA Expression Atlas, Epigenetics, Infectious Diseases and Pathogenesis, Alternative RNA Splicing, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Others), By Product (Instruments {Kits & Reagents, miRNA & siRNA, Reverse Transcriptases & RT-PCR, RNA Extraction & Purification, RNA Interference, Others}, Services), By End-use (Government Institutes & Academic Centers, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Hospitals & Clinics), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. Global RNA Transcriptomics Market size was valued at USD 4.68 Billion in 2021 and is projected to reach USD 12.72 Billion by 2028, growing at a CAGR of 13.63% from 2021 to 2028 according to a new report by 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. #RNATranscriptomics 𝐘𝐨𝐮 𝐜𝐚𝐧 𝐜𝐡𝐞𝐜𝐤 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:⬇ https://lnkd.in/dPhGpygz 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐈𝐧 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:⬇ ACOBIOM Affymetrix Agilent Technologies BGI Genomics bioMérieux Bio-Rad Laboratories CD Genomics Cenix BioScience Danaher Corporation Eurofins Scientific Finland Oy GeneDx GenXPro GmbH roche agency Illumina LC Sciences Lexogen Merck KGaA, Darmstadt, Germany Oxford Nanopore Technologies Pacific BioScience Inc. Partek, an Illumina company Promega Corporation PROMEGA QIAGEN Sequentia Biotech Standard BioTools Takara Bio USA, Inc. Thermo Fisher Scientific Zymo Research Corp
-
-
RNA-based therapies treat a wide range of diseases—from genetic disorders to infections to cancers. Breakthrough tech from EnPlusOne Biosciences could make treatments cheaper, better, and more accessible. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🔬 EnPlusOne Biosciences' new enzymatic RNA synthesis process allows for a wider range of RNA chemistries, enhancing the potential for diverse RNA-based therapies. 🌿 Originating from the Wyss Institute at Harvard University, the ezRNA™ platform uses water and enzymes to produce RNA, eliminating toxic byproducts and ensuring sustainability. 📈 As published in Nature Biotechnology, the new process achieves 95% efficiency and supports rapid scale-up to address the increasing global demand for RNA therapeutics. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲: https://lnkd.in/dnkHTWf9
Harvard Scientists Publish Details of Enzymatic RNA Synthesis Tech Commercialized by EnPlusOne
genengnews.com
-
RNA Analysis Market Size, Share & Trends Analysis Report By Technology (Real Time-PCR (qPCR) Technology, Microarray Technology, Sequencing Technology, Others), By Product (Instruments, Kits & Reagents, miRNA & siRNA, Reverse Transcriptases & RT-PCR, RNA Extraction & Purification, RNA Interference, Others, Services), By Application (Construction of RNA Expression Atlas, Epigenetics, Infectious Diseases and Pathogenesis, Alternative RNA Splicing, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Others), By End-use (Government Institutes & Academic Centers, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Hospitals & Clinics), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. Global RNA Analysis Market size was valued at USD 10.49 Billion in 2021 and is projected to reach USD 25.45 Billion by 2028, growing at a CAGR of 13.68% from 2021 to 2028 according to a new report by 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. #RNAAnalysis 𝐘𝐨𝐮 𝐜𝐚𝐧 𝐜𝐡𝐞𝐜𝐤 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:⬇ https://lnkd.in/dTBUriKR 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐈𝐧 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:⬇ ACOBIOM Affymetrix Agilent Technologies BGI Genomics bioMérieux Bio-Rad Laboratories CD Genomics Cenix BioScience Danaher Corporation Eurofins Scientific Finland Oy GeneDx GenXPro GmbH roche agency Illumina LC Sciences Lexogen Merck KGaA, Darmstadt, Germany Oxford Nanopore Technologies Pacific BioScience Inc. Partek, an Illumina company Promega Corporation PROMEGA QIAGEN Sequentia Biotech Standard BioTools Takara Bio USA, Inc. Thermo Fisher Scientific Zymo Research Corp
-
-
Co-founder & CBO @InsideTx | Nanoparticle/RNA-LNP formulation and microfluidics expert | 50+inovative nanoparticles formulation systems provided: Eli Lilly, Servier, ETHZ, UCL, Moderna, Ribopro
🔬 Exciting Research Alert! 🔬 Are you interested in the latest advancements in RNA therapeutics delivery by LNP? Check out this groundbreaking study published in Scientific Reports! The article "A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient" dives deep into optimizing lipid nanoparticle formulations for RNA cargo delivery. 🌟 One of the key takeaways is that contrary to expectations, there is no significant correlation between #RNA size and Lipid #nanoparticles (#LNP) size! In fact, the main elements driving nanoparticle size are lipid composition (including PEG concentration) and Total Flow Rate (when using a microfluidic system). 📚 Dive into the full article here: https://lnkd.in/eMAY4Q6E Follow Inside Tx for more updates on cutting-edge research in RNA-LNP therapeutics! Let's keep pushing the boundaries of science together! 💡🚀
A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient - Scientific Reports
nature.com
-
🎊 Our latest paper "Peptide Dendrimers Transfecting CRISPR/Cas9 Plasmid DNA: Optimization and Mechanism" by Susanna Joelle Zamolo PhD, Elena Zakharova, Ph.D., Lise Boursinhac, Florian Hollfelder, Tamis Darbre, and Jean-Louis Reymond is now published on Chemical Biology #RSCChemBio#RSCChemBio! We optimize a peptide dendrimer transfection reagent to deliver a large CRISPR/Cas9 plasmid DNA into cells, elucidate its delivery mechanism, and demonstrate its gene editing efficiency. 👉 Read the full version: https://lnkd.in/ebcdsW9T DCBP - Department of Chemistry, Biochemistry and Pharmaceutical Sciences (University of Bern) University of Bern Reymond Group Abstract Gene editing by CRISPR/Cas9 offers great therapeutic opportunities but requires delivering large plasmid DNA (pDNA) into cells, a task for which transfection reagents are better suited than viral vectors. Here we performed a structure–activity relationship study of Z22, a D-enantiomeric, arginine containing, lipidated peptide dendrimer developed for pDNA transfection of a CRISPR/Cas9 plasmid co-expressing GFP. While all dendrimer analogs tested bound pDNA strongly and internalized their cargo into cells, D-chirality proved essential for transfection by avoiding proteolysis of the dendrimer structure required for endosome escape and possibly crossing of the nuclear envelope. Furthermore, a cysteine residue at the core of Z22 proved non-essential and was removed to yield the more active analog Z34. This dendrimer shows >83% GFP transfection efficiency in HEK cells with no detrimental effect on cell viability and promotes functional CRISPR/Cas9 mediated gene editing. It is accessible by solid-phase peptide synthesis and therefore attractive for further development.
-
-
RNA Transcriptomics Market Size, Share & Trends Analysis Report By Technology (Real Time-PCR (qPCR) Technology, Microarray Technology, Sequencing Technology, Others), By Application (Construction of RNA Expression Atlas, Epigenetics, Infectious Diseases and Pathogenesis, Alternative RNA Splicing, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Others), By Product (Instruments {Kits & Reagents, miRNA & siRNA, Reverse Transcriptases & RT-PCR, RNA Extraction & Purification, RNA Interference, Others}, Services), By End-use (Government Institutes & Academic Centers, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Hospitals & Clinics), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. Global RNA Transcriptomics Market is projected to reach USD 12.72 Billion by 2028, growing at a CAGR of 13.63% from 2021 to 2028 according to a new report by 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. 𝐘𝐨𝐮 𝐜𝐚𝐧 𝐜𝐡𝐞𝐜𝐤 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:⬇ https://lnkd.in/dPhGpygz 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐈𝐧 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭:⬇ Illumina QIAGEN Agilent Technologies Roche Thermo Fisher Scientific. Eurofins Scientific Finland Oy Merck KGaA, Darmstadt, Germany Bio-Rad Laboratories Pacific BioScience Inc. Affymetrix Danaher Corporation Promega Corporation
-
-
CRISPR Market to Grow $7.1 Billion by 2028 Download Sample PDF Report-https://lnkd.in/ddZq79mv The global CRISPR market in terms of revenue was estimated to be worth $3.4 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028. Companies Working in the Market CRISPR QC CRISPR Therapeutics SNIPR Biome - A CRISPR Company Twist Bioscience Integrated DNA Technologies Beam Therapeutics Caribou Biosciences Chan Zuckerberg Biohub Network Inari Aldevron Sapio Sciences Benson Hill Inscripta, Inc. Arbor Biotechnologies Sherlock Biosciences KSQ Therapeutics, Inc. Innovative Genomics Institute Graphite Bio Cure Rare Disease Locus Biosciences, Inc. Namocell Miroculus Santa Cruz Biotechnology (SCBT) Applied StemCell VectorBuilder Discover Echo Inc. CellFE Kytopen Molecular Assemblies, Inc. Cellecta, Inc. BDG LifeSciences Mirimus Horizon Discovery John Innes Centre Intellia Therapeutics, Inc. Mammoth Biosciences Editas Medicine Arsenal Biosciences, Inc. Eurofins Genomics India Pvt Ltd. Polyplus now part of Sartorius
-
